GlassScriptPhysician profile
Kathryn D Convers
NPI 1043417769
$6,519.35
in general payments reported to CMS, 2019-2025
32 companies · $1,142 in 2025
The $1,142 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $657 · 2021: $828 · 2022: $764 · 2023: $1,092 · 2024: $936 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,915 · Education: $255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,914.77 |
| Education | $254.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,103.89 | 2019-2025 | Dupixent |
| Csl Behring | $924.03 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Genzyme Corporation | $828.78 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $710.09 | 2020-2025 | Cuvitru, Takhzyro |
| Astrazeneca Pharmaceuticals LP | $475.09 | 2019-2025 | Tezspire, Fasenra |
| Pfizer INC. | $283.04 | 2019-2025 | |
| Glaxosmithkline, LLC. | $229.60 | 2019-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $191.39 | 2020-2025 | |
| Shire North American Group INC | $183.41 | 2019 | |
| Optinose US, INC. | $162.63 | 2019-2025 | |
| Pharming Healthcare, INC. | $141.42 | 2019-2025 | Ruconest |
| Biocryst US Sales Co., LLC | $130.71 | 2021-2025 | Orladeyo |
| Octapharma USA, INC. | $112.12 | 2019-2021 | |
| Kaleo, INC. | $110.27 | 2019-2022 | |
| Genentech USA, INC. | $109.09 | 2019-2025 | Xolair |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $98.00 | 2024 | |
| Amgen INC. | $93.10 | 2022-2025 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.43 | 2019-2022 | |
| Covis Pharma Gmbh | $72.82 | 2021 | |
| Sunovion Pharmaceuticals INC. | $71.25 | 2019 | |
| Leo Pharma INC. | $63.55 | 2023-2025 | Adbry |
| Grifols USA, LLC | $61.40 | 2022-2025 | Xembify |
| Lilly USA, LLC | $43.97 | 2025 | Ebglyss |
| Horizon Therapeutics Plc | $43.02 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $34.42 | 2021 | |
| Galderma Laboratories, L.P. | $33.76 | 2025 | Nemluvio |
| Incyte Corporation | $29.75 | 2025 | Opzelura |
| Ionis Pharmaceuticals, INC. | $25.00 | 2025 | |
| Phadia US INC. | $22.47 | 2024 | Immunocap |
| Azurity Pharmaceuticals, INC. | $21.98 | 2025 | Alvesco |
| Ars Pharmaceuticals Operations, INC. | $17.57 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $15.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Convers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.